TPM
PRTK

T2 Partners Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

T2 Partners Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-5,008
Closed -$182K – 58
2013
Q2 		$182K Buy
+5,008
New +$215K 0.16% 55

Other funds holding PRTK

RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LOM
Loeb Offshore Management New York $547M AUM 50.11% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

T2 Partners Management's PRTK Position: Q3 2013 in Review

T2 Partners Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2013, closing a stake of 5,008 shares — an estimated $182K sold.

T2 Partners Management first reported a position in PRTK in Q2 2013 and held it in 1 quarter. The position peaked at $182K in Q2 2013. 42 funds tracked by Wall St. Rank hold PRTK as of Q3 2013.

  • T2 Partners Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2013 after selling out during the quarter.
  • T2 Partners Management sold 5,008 Paratek Pharmaceuticals, Inc. shares in Q3 2013, an estimated $182K.
  • T2 Partners Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 1 quarter.
  • T2 Partners Management's Paratek Pharmaceuticals, Inc. position peaked at $182K in Q2 2013.
  • 42 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2013.

Based on T2 Partners Management's 13F filing for Q3 2013, filed 12 Nov 2013.